[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fnwXABV0CHW3IaxJUFG0hdzx-LywycikqwXiXI9zJ-B8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":33,"rows":40},"Universidade Estadual de Londrina",[4],49,false,3,2,3307,0,46,[14,17,20,22,24,26,28,30],{"name":15,"count":16},"Healthy",5,{"name":18,"count":19},"Urinary Incontinence",4,{"name":21,"count":8},"Pulmonary Disease, Chronic Obstructive",{"name":23,"count":8},"Thirst",{"name":25,"count":8},"Aging",{"name":27,"count":8},"Recruitment",{"name":29,"count":8},"Pain",{"name":31,"count":9},"Patellofemoral Pain Syndrome",[],[34,35,36,37,38,39],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[41,72,101,128],{"intervention":42,"totalTrials":43,"cells":44},"folate treatment",1,{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":51,"PHASE4":53,"NA":70},{"trials":46,"activeCount":11},[],{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[55],{"nctId":56,"briefTitle":57,"status":58,"phases":59,"completion":60,"start":61,"enrollment":62,"conditions":63,"interventions":69},"NCT00317005","Uremic Hyperhomocysteinemia -A Folate Trial for Possible Prevention of Cardiovascular Events","COMPLETED",[38],"2005-03","2003-04",186,[64,65,66,67,68],"Uremia","Chronic Renal Failure","Hemodialysis","Hyperhomocysteinemia","Cardiovascular Disease",[42],{"trials":71,"activeCount":11},[],{"intervention":73,"totalTrials":43,"cells":74},"N-acetylcysteine",{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":81,"PHASE4":97,"NA":99},{"trials":76,"activeCount":11},[],{"trials":78,"activeCount":11},[],{"trials":80,"activeCount":11},[],{"trials":82,"activeCount":11},[83],{"nctId":84,"briefTitle":85,"status":86,"phases":87,"primaryCompletion":88,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":96},"NCT02124525","N-acetylcysteine for Tobacco Smoking","UNKNOWN",[37],"2014-04","2014-05","2013-02",32,[93,94,95],"Tobacco Smoking","Oxidative Stress","Inflammation",[73],{"trials":98,"activeCount":11},[],{"trials":100,"activeCount":11},[],{"intervention":102,"totalTrials":43,"cells":103},"Budesonide Nasal",{"EARLY_PHASE1":104,"PHASE1":106,"PHASE2":108,"PHASE3":110,"PHASE4":112,"NA":114},{"trials":105,"activeCount":11},[],{"trials":107,"activeCount":11},[],{"trials":109,"activeCount":11},[],{"trials":111,"activeCount":11},[],{"trials":113,"activeCount":11},[],{"trials":115,"activeCount":11},[116],{"nctId":117,"briefTitle":118,"status":86,"phases":119,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":126},"NCT05541419","Use of Budesonide Diluted to Maximum Clinical Treatment of Patients With Chronic Rhinosinusitis With Polyoposis.",[39],"2022-08-25","2025-08-10","2018-08-10",60,[125],"Chronic Rhinosinusitis (Diagnosis)",[102,127],"Placebos",{"intervention":127,"totalTrials":43,"cells":129},{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":136,"PHASE4":138,"NA":140},{"trials":131,"activeCount":11},[],{"trials":133,"activeCount":11},[],{"trials":135,"activeCount":11},[],{"trials":137,"activeCount":11},[],{"trials":139,"activeCount":11},[],{"trials":141,"activeCount":11},[142],{"nctId":117,"briefTitle":118,"status":86,"phases":143,"primaryCompletion":120,"completion":121,"start":122,"enrollment":123,"conditions":144,"interventions":145},[39],[125],[102,127]]